Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy.

Toll SA, Tran HN, Cotter J, Judkins AR, Tamrazi B, Biegel JA, Dhall G, Robison NJ, Waters K, Patel P, Cooper R, Margol AS.

Oncotarget. 2019 Jan 11;10(4):551-557. doi: 10.18632/oncotarget.26560. eCollection 2019 Jan 11.

2.

A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group.

Margol AS, Yeo KK, Xia C, Onar A, Robison NJ, Freyer DR, Dhall G.

J Neurooncol. 2018 Dec;140(3):575-582. doi: 10.1007/s11060-018-2983-5. Epub 2018 Sep 1.

PMID:
30173409
3.

Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.

Robison NJ, Yeo KK, Berliner AP, Malvar J, Sheard MA, Margol AS, Seeger RC, Rushing T, Finlay JL, Sposto R, Dhall G.

J Neurooncol. 2018 May;138(1):199-207. doi: 10.1007/s11060-018-2791-y. Epub 2018 Feb 9.

4.

Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.

Bayliss J, Mukherjee P, Lu C, Jain SU, Chung C, Martinez D, Sabari B, Margol AS, Panwalkar P, Parolia A, Pekmezci M, McEachin RC, Cieslik M, Tamrazi B, Garcia BA, La Rocca G, Santi M, Lewis PW, Hawkins C, Melnick A, David Allis C, Thompson CB, Chinnaiyan AM, Judkins AR, Venneti S.

Sci Transl Med. 2016 Nov 23;8(366):366ra161.

5.

Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia.

Xu J, Margol AS, Shukla A, Ren X, Finlay JL, Krieger MD, Gilles FH, Couch FJ, Aziz M, Fung ET, Asgharzadeh S, Barrett MT, Erdreich-Epstein A.

Front Oncol. 2015 Aug 27;5:191. doi: 10.3389/fonc.2015.00191. eCollection 2015.

6.

Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.

Bl├╝ml S, Margol AS, Sposto R, Kennedy RJ, Robison NJ, Vali M, Hung LT, Muthugounder S, Finlay JL, Erdreich-Epstein A, Gilles FH, Judkins AR, Krieger MD, Dhall G, Nelson MD, Asgharzadeh S.

Neuro Oncol. 2016 Jan;18(1):126-31. doi: 10.1093/neuonc/nov097. Epub 2015 Aug 8.

7.

Tumor-associated macrophages in SHH subgroup of medulloblastomas.

Margol AS, Robison NJ, Gnanachandran J, Hung LT, Kennedy RJ, Vali M, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Fouladi M, Gilles FH, Judkins AR, Sposto R, Asgharzadeh S.

Clin Cancer Res. 2015 Mar 15;21(6):1457-65. doi: 10.1158/1078-0432.CCR-14-1144. Epub 2014 Oct 24.

8.

Pathology and diagnosis of SMARCB1-deficient tumors.

Margol AS, Judkins AR.

Cancer Genet. 2014 Sep;207(9):358-64. doi: 10.1016/j.cancergen.2014.07.004. Epub 2014 Aug 1. Review.

PMID:
25246033
9.

PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas.

Erdreich-Epstein A, Robison N, Ren X, Zhou H, Xu J, Davidson TB, Schur M, Gilles FH, Ji L, Malvar J, Shackleford GM, Margol AS, Krieger MD, Judkins AR, Jones DT, Pfister SM, Kool M, Sposto R, Asgharzadeh S.

Clin Cancer Res. 2014 Feb 15;20(4):827-36. doi: 10.1158/1078-0432.CCR-13-2053. Epub 2013 Dec 3. Erratum in: Clin Cancer Res. 2015 Sep 15;21(18):4243. Asgharazadeh, Shahab [corrected to Asgharzadeh, Shahab].

Supplemental Content

Loading ...
Support Center